GlassScriptPhysician profile
Spencer David Stott
NPI 1699445601
$4,750.55
in general payments reported to CMS, 2019-2025
23 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $96.18 · 2023: $1,100 · 2024: $1,567 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,652 · Education: $2.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,651.97 |
| Education | $2.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.13 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $506.71 | 2024-2025 | Fanapt |
| Alkermes, INC. | $405.58 | 2023-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $374.49 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $368.41 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bausch Health US, LLC | $241.60 | 2023-2025 | Aplenzin |
| Lundbeck LLC | $186.49 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $170.33 | 2023-2024 | Auvelity |
| Corium, LLC | $144.49 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $109.85 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $103.37 | 2023-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $81.90 | 2023-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $80.70 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $68.33 | 2024-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $63.91 | 2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $47.28 | 2024 | Zurzuvae |
| Tris Pharma INC | $38.27 | 2023-2024 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $28.24 | 2022 | |
| Acadia Pharmaceuticals INC | $23.99 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.34 | 2025 | Relexxii |
| Supernus Pharmaceuticals, INC. | $18.59 | 2025 | Qelbree |
| Neos Therapeutics, LP | $16.42 | 2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $15.13 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Stott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.